United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
569.11
+2.12 (0.37%)
Apr 28, 2026, 4:00 PM EDT - Market closed
United Therapeutics Employees
United Therapeutics had 1,400 employees as of December 31, 2025. The number of employees increased by 95 or 7.28% compared to the previous year.
Employees
1,400
Change (1Y)
95
Growth (1Y)
7.28%
Revenue / Employee
$2,273,357
Profits / Employee
$953,357
Market Cap
24.94B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,400 | 95 | 7.28% |
| Dec 31, 2024 | 1,305 | 137 | 11.73% |
| Dec 31, 2023 | 1,168 | 183 | 18.58% |
| Dec 31, 2022 | 985 | 20 | 2.07% |
| Dec 31, 2021 | 965 | 15 | 1.58% |
| Dec 31, 2020 | 950 | 30 | 3.26% |
| Dec 31, 2019 | 920 | 60 | 6.98% |
| Dec 31, 2018 | 860 | 60 | 7.50% |
| Dec 31, 2017 | 800 | 50 | 6.67% |
| Dec 31, 2016 | 750 | 0 | - |
| Dec 31, 2015 | 750 | 10 | 1.35% |
| Dec 31, 2014 | 740 | 34 | 4.82% |
| Dec 31, 2013 | 706 | 83 | 13.32% |
| Dec 31, 2012 | 623 | 80 | 14.73% |
| Dec 31, 2011 | 543 | 23 | 4.42% |
| Dec 31, 2010 | 520 | 110 | 26.83% |
| Dec 31, 2009 | 410 | 50 | 13.89% |
| Dec 31, 2008 | 360 | 40 | 12.50% |
| Dec 31, 2007 | 320 | 35 | 12.28% |
| Dec 31, 2006 | 285 | 75 | 35.71% |
| Dec 31, 2005 | 210 | 40 | 23.53% |
| Dec 31, 2004 | 170 | 10 | 6.25% |
| Dec 31, 2003 | 160 | 10 | 6.67% |
| Dec 31, 2002 | 150 | 22 | 17.19% |
| Dec 31, 2001 | 128 | 18 | 16.36% |
| Dec 31, 2000 | 110 | 47 | 74.60% |
| Dec 31, 1999 | 63 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Hims & Hers Health | 2,442 |
UTHR News
- 6 days ago - United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026 - Business Wire
- 8 days ago - United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026 - Business Wire
- 20 days ago - United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure - Business Wire
- 4 weeks ago - United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 - Business Wire
- 6 weeks ago - United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine - Business Wire
- 7 weeks ago - United Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program - Business Wire
- 2 months ago - United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference - Business Wire